Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study is a phase 3, randomised interventional study registered as NCT07132463 by Fudan University, with a registry enrolment figure of 196 participants, started 2025-08-12 and due to reach its primary completion in 2027-12. Interventions recorded: Long-course chemoradiotherapy; Tislelizumab combined with the CAPOX regimen; CAPOX regimen. Conditions listed: Rectal Cancer. Primary outcome: Anus preservation rate. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.